Impact Investments in Cancer Care Innovation
We provide a full-suite hybrid VC & PE
funding to scale health care breakthroughs
Growth
Our Portfolio of Innovative Companies
We were part of these companies’ successful growth,
leading to a real change in today’s healthcare
20+ Clinics in Europe
Public Listed on NASDAQ
Experts in Integrative Medicine
Acquired in 2017
Public Listed on NYSE
Early-stage Investors

Latest News
Alpha Tau reports positive interim results from U.S. glioblastoma trial
Alpha Tau announced new interim results from its U.S. REGAIN trial of Alpha DaRT in recurrent glioblastoma. All eight treated patients remained alive as of November 11, 2026, and median overall survival has not been reached. The first six evaluable patients, with a median follow-up of 6.9 months, showed a 100% objective response rate, 100% feasibility and no unanticipated serious adverse events.
Alpha Tau Receives FDA Approval to Expand U.S. REGAIN Trial of Alpha DaRT® for Recurrent Glioblastoma
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement expanding its U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial.
Amethyst's HBI Oncology Community – a new platform driving cross-sector collaboration in cancer care.
Amethyst Healthcare Group is proud to launch a new dedicated Oncology Community with Healthcare Business International (HBI) designed to bring the industry leaders together and accelerate progress in oncology.